Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.

This study developed the CATNIP computational model, which uses biological and chemical information to successfully identify drug repurposing opportunities for various conditions, including Parkinson’s disease and Type 2 Diabetes.

This case report describes a 29-year-old male with relapsing hepatitis A, a rare complication of acute hepatitis A virus infection, characterized by prolonged elevated liver chemistries and persistent HAV IgM, managed conservatively.

A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.

This review outlines drug repurposing as an efficient, low-cost strategy to identify new uses for existing drugs, highlighting various computational and experimental approaches as well as publicly available databases to aid in personalized pharmacotherapy.

This study found that a 50% ethanolic extract of Adiantum capillus had significant analgesic and anti-inflammatory effects in animals, particularly at the highest tested dose of 300 mg/kg.

This case report describes successful treatment of valproate-induced hyperammonemia in a 79-year-old man using lactulose, marking the first such documented use for this condition.

This article reviews potential drug and herbal interactions with warfarin that may increase bleeding risk, and reports no new clinical results.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

In this study, chemotherapy-induced adverse drug reactions were common in cancer patients, highlighting the need for better pharmacovigilance and personalized treatment strategies to reduce their occurrence and severity.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

The study found that the combined administration of regulatory T cells and rapamycin improved outcomes in an experimental model of chronic graft-versus-host disease.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.

The patches could quickly deliver epilepsy treatment and reduce seizures.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This article discusses the growing trend of repurposing existing medications for innovative therapeutic uses and highlights the need for pharmacy practitioners to be informed about accessing clinical evidence related to these applications, but it reports no new results.

This study found that 4-aminopyridine significantly improved skin wound healing by enhancing wound closure, tissue regeneration, and cellular interactions involved in repair processes.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

In this case report, azathioprine induced sudden hair loss and pancytopenia in a 42-year-old female patient, but discontinuing the drug and providing supportive care resulted in complete recovery and hair regrowth within 2.5 months.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.